Home | Contact Us | Brochure  | User Guide
0
Username
Password
Forgot Password
Capitaline Newswire App Google Play Capitaline Newswire App Store
02 Apr 2026 00:04 Sensex 73,319.55 185.23 (0.25%) || Nifty 22,713.10 33.70 (0.15%) 00
  AMC
  Single Scheme
  Multi Schemes
  Comparison
  NFO
  Charts
  MF Updates
  Miscellaneous
  Defined Sets
News
Top Equity Holdings by AMC
Interview with Fund Managers Back
08 Jan 2026 20:29
Venus Remedies receives marketing authorisation for Ceftazidime + Avibactam in Indonesia

Venus Remedies has received marketing authorisation in Indonesia for its antibiotic combination Ceftazidime + Avibactam, granted by the relevant Indonesian drug regulatory authority. This approval marks the first marketing authorisation for Ceftazidime + Avibactam for the Company in Indonesia.

The product is indicated for the treatment of serious infections caused by multi-drug resistant gram-negative pathogens, including complicated intra-abdominal infections and complicated urinary tract infections

Powered by Capital Market - Live News
Other Stories
RBL Bank allots 2.33 lakh...
 (2-Apr  19:50)
Aditya Birla Capital allo...
 (2-Apr  19:43)
ICICI Lombard General Ins...
 (2-Apr  19:42)
Board of Zensar Technolog...
 (2-Apr  19:39)
Cupid invests 25% of Rs 3...
 (2-Apr  19:26)
Birlasoft appoints Vikram...
 (2-Apr  17:50)
Emcure Pharmaceuticals re...
 (2-Apr  17:46)
JLR announces wholesale a...
 (2-Apr  17:40)
Emami to acquire balance ...
 (2-Apr  17:38)
LG Electronics India sell...
 (2-Apr  17:36)
  FAQs  |  SEBI  |  AMFI  |  BSE  |  NSE
Glossary  |  Disclaimer   |  Privacy Policy   © Copyright 2022 All rights Reserved. Capital Market Publishers India Pvt. Ltd.